Abstract 1937P
Background
To clarify the clinicopathological features and clinical outcomes of histological subtypes of papillary thyroid carcinoma (PTC) in the pediatric and adolescent population treated at a single institution.
Methods
A total of 153 PTC patients ≤18 years of age who underwent initial surgery between 1979 and 2019 were investigated. The most common subtypes included classic PTC in 124 (81%), solid variant in 16 (10%), diffuse sclerosing variant in 7 (5%), and follicular variant in 6 (4%). Cause-specific survival (CSS) and disease-free survival (DFS) rates were calculated by the Kaplan–Meier method.
Results
There were 135 female and 18 male patients, with a mean age at the time of surgery of 16 (range, 8-18) years, and 5% (8 patients) were ≤10 years of age at diagnosis. At initial surgery, 49 patients (32%) had lymph node metastases diagnosed preoperatively (cN1), 16 (10%) had gross extrathyroidal extension (ETE), and 18 (12%) had lung metastases. Total thyroidectomy was performed in 55 (36%) patients, and 98 (64%) patients underwent less than total thyroidectomy. During a mean follow-up of 16 years, 3 patients died of their disease, and 34 patients had recurrent disease. The 30-year CSS rate was 97.2%, and the 30-year DFS rate was 65.0%. On univariate analysis, extensive ETE (p=0.001) and cN1 (p=0.003), but not histological subtype (p=0.21), were associated with disease recurrence. Extensive ETE and cN1 were identified as significant factors related to DFS on multivariate analysis (hazard ratio (HR) 5.2, confidence interval (CI) 1.9-12.4, p=0.0028; HR 3.2, CI.6-6.6, p=0.0021).
Conclusions
The prognosis of pediatric patients with PTC was good, but recurrence was common. In pediatric PTC, histological subtype did not affect survival and recurrence.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1936P - Treatment outcomes of patients with anaplastic thyroid carcinoma (atc): Multicentric data from spanish national registry (regetne-tiroides)
Presenter: José Miguel Rodellar
Session: Poster session 18
1938P - Nomogram for predicting lung metastases in patients with papillary thyroid cancer under 55 years old
Presenter: Huiyun Yang
Session: Poster session 18
1939P - BrafV600E-induced cancer inflammation in a mouse model of thyroid tumorigenesis
Presenter: Sima Kumari
Session: Poster session 18
1940TiP - Sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory thyroid carcinoma and anaplastic thyroid carcinoma: The phase II SETHY, GETNE-T2318 trial design
Presenter: Alejandro Garcia Alvarez
Session: Poster session 18
1941TiP - Neoadjuvant pembrolizumab in high-risk thyroid cancer (NePenTHe)
Presenter: Claudia Leli
Session: Poster session 18
1924P - Efficacy and safety of lenvatinib in patients with chemotherapy-naive advanced or recurrent thymic carcinoma: A multicenter retrospective study
Presenter: Daisuke Hazama
Session: Poster session 18
1923P - Real-world management and outcome of thymic carcinomas in a tertiary German center
Presenter: Antonia Margineanu
Session: Poster session 18
1922P - Targeted resequencing designed specifically for thymic epithelial tumours confirmed the high prevalence of GTF2I mutations
Presenter: Iacopo Petrini
Session: Poster session 18
1921P - Molecular analysis of mesothelioma reveals mutations as prognostic biomarkers for patients treated with the combination of ipilimumab and nivolumab
Presenter: Angelica Rigutto
Session: Poster session 18
1920P - Multiomics analysis of malignant pleural mesothelioma and the effect of immune checkpoint inhibitors
Presenter: Akiko Tateishi
Session: Poster session 18